2016 Fiscal Year Final Research Report
Development of the new cancer immunotherapy using iPS- derived CTLs for cancer stem cells
Project/Area Number |
26461923
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Wakayama Medical University |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Keywords | iPS細胞 / 樹状細胞 / 癌免疫療法 |
Outline of Final Research Achievements |
We have reported an effective antitumor immune response of cytotoxic T lymphocytes (CTLs) by vaccine therapy using dendritic cells (DCs). Moreover, we have used the induced pluripotent stem (iPS) cell-derived DCs (iPSDCs). In the present study, we used carcinoembryonic antigen (CEA) of gastrointestinal cancers, and examined an actual antitumor effect using a CEA transgenic mouse model. We adenovirally transduced the CEA gene into mouse iPSDCs (miPSDCs) and immunized mice once with the genetically modified DCs. The cytotoxic activity of CTLs and the therapeutic efficacy of this vaccination were assayed. Our results showed significantly higher cytotoxicity against MC38-CEA and significantly higher therapeutic efficacy in mice administered with miPSDCs-CEA than in mice immunized with PBS and miPSDCs-LacZ. Therefor, this vaccination strategy using genetically modified iPSDCs expressing CEA may be useful for future clinical application against patients with a gastrointestinal cancer.
|
Free Research Field |
腫瘍免疫学
|